Journal
PLOS BIOLOGY
Volume 12, Issue 7, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pbio.1001906
Keywords
-
Categories
Funding
- Cancer Research UK
- Rosetrees Trust
- Academy of Medical Sciences
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- MRC [MC_UP_1203/1] Funding Source: UKRI
- Academy of Medical Sciences (AMS) [AMS-SGCL7-Murugaesu, AMS-SGCL7-Krebs] Funding Source: researchfish
- Cancer Research UK [17861, 17862, 17891, 15953, 17863, 17786, 17892, 19310, 19278] Funding Source: researchfish
- Medical Research Council [MC_UP_1203/1] Funding Source: researchfish
- National Institute for Health Research [CL-2011-18-001, CL-2011-06-002] Funding Source: researchfish
Ask authors/readers for more resources
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available